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One approach to prevent tissue destruction by autoimmune attack in organ-specific 
autoimmune diseases is to protect the target tissue from autoimmune reaction irrespective of its 
persistent activity.  To provide proof-of-principle for the feasibility of this approach, the 
immuno-regulatory molecules, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
and indoleamine 2, 3-dioxygenase (IDO), were expressed in the thyroid glands using adenovirus 
vector in non-obese diabetic (NOD)-H2h4 mice that spontaneously develop thyroiditis.  Mice 
were anesthetized, and the thyroid glands were exposed by neck dissection followed by in situ 
infection with adenovirus vector (5 x 1010 particles/mouse) twice or thrice, starting one day or 
four weeks before mice were supplied with NaI water.  After 8 weeks of NaI provision, the 
extent of thyroiditis, serum titers of anti-thyroglobulin (Tg) antibodies and cytokine expression 
in the spleen were examined.  In situ infection of adenovirus expressing TRAIL or IDO, but 
not green fluorescent protein, significantly suppressed thyroiditis scores.  However, anti-Tg 
antibody titers and expression levels of cytokines (IFN- and IL-4) in the spleen remained 
unaltered.  Importantly, adenovirus infection 4 weeks after NaI provision was also effective at 
suppressing thyroiditis.  The suppressive effect of TRAIL appears to be mediated at least 
partly by accumulation of CD4+Foxp3+ regulatory T cells into the thyroid glands.  Thus, 
localized expression of immuno-regulatory molecules efficiently protected the thyroid glands 
from autoimmune attack without changing the systemic autoimmunity in NOD-H2h4 mice.  
This kind of immunological intervention, although it does not suppress autoimmune reactivity, 





   There appear to be two distinct 
approaches to prevent destruction of the 
target tissues by autoimmune attack in 
organ-specific autoimmune diseases.  One is 
to dampen the abnormally activated 
autoantigen-specific immune responses, and 
the other to protect the target tissues from 
autoimmune attack irrespective of persistent 
autoimmunity.  The feasibility of the latter 
approach can be investigated by localized 
expression of the immuno-regulatory 
molecules in the target tissues of animal 
models of organ-specific autoimmune 
diseases.  In this case, immuno-suppression 
would be limited to the microenvironments 
surrounding the tissue of expression. 
Tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) (1) and 
indoleamine 2, 3-dioxygenase (IDO) (2) are 
the immuno-regulatory molecules recently 
identified.  TRAIL is a member of the TNF 
super-family and is constitutively expressed 
in a variety of cell types including 
lymphocytes and natural killer cells.  
Although TRAIL was first reported to 
selectively kill tumor cells or virus-infected 
cells by inducing apoptosis, recent studies 
reveal that TRAIL also suppresses or kills 
activated T cells (1, 3, 4).  Indeed genetic 
disruption of TRAIL gene or chronic TRAIL 
blockade by soluble death receptor 5, one of 
the receptors for TRAIL, exacerbates 
autoimmune diseases such as 
collagen-induced arthritis and 
streptozocin-induced diabetes in mice (5, 6).  
Conversely, TRAIL-expressing professional 
antigen-presenting dendritic cells (DCs) 
suppress immune responses in autoimmune 
disease and graft-versus-host disease (3, 4, 
7).   
IDO is a rate-limiting enzyme in the 
catabolism of tryptophan, and is expressed in 
a series of tissues, particularly in lymphoid 
organs and placenta (2).  IDO was originally 
shown to inhibit proliferation of intracellular 
pathogens and tumor cells through 
consumption of the essential amino acid 
tryptophan.  Subsequently, however, 
immunosuppression has been shown to be an 
additional role for IDO (2).  Importantly, 
maintenance of pregnancy is associated with 
a role for tryptophan catabolism in 
preventing the proliferation of allogenic T 
cells against paternal antigens expressed on 
fetus (8) and the expression of IDO in 
antigen-presenting cells suppresses 
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autoreactive T cells (9).  Local tryptophan 
deficiency and accumulation of its 
metabolites such as kynurenine by IDO are 
thought to exert its action (5).  
1-methyl-tryptophan, a pharmacological 
inhibitor of IDO, has been shown to 
exacerbate experimental autoimmune 
encephalomyelitis and autoimmune colitis 
(10, 11), indicating IDO to be a potent 
immuno-regulator in autoimmunity.  In 
contrast, overexpression of exogenous IDO 
results in immunosuppression and tolerance 
in animal models of tumor immunity and 
transplantation (12 - 14).     
   Non-obese diabetic (NOD)-H2h4 mice 
spontaneously develop anti-thyroglobulin 
(Tg) autoantibodies and intrathyroidal 
lymphocyte infiltration when supplied with 
iodine in the drinking water, and are widely 
used as a model of autoimmune thyroiditis, 
one of the common organ-specific 
autoimmune diseases (15, 16).  
Autoimmune thyroiditis in these mice is 
considered to be a T cell-mediated 
autoimmune disease that results in the 
destruction of the thyroid follicles (17).   
The present study was thus designed to 
study the effect of localized expression of the 
above-mentioned immuno-regulatory 
molecules, TRAIL and IDO, on development 
of thyroid autoimmunity in NOD-H2h4 mice, 
by using replication-defective recombinant 
adenovirus vector as a gene delivery vehicle.   
We here show adenovirus-mediated 
thyroidal expression of TRAIL or IDO 
provides an efficient immunological shield 
against thyroiditogenic autoimmune process 
without altering the systemic immune system.  
Thus this kind of immunological intervention 
may have a potential for treating 
organ-specific autoimmune diseases. 
 
 
MATERIALS AND METHODS 
 
Mice 
   NOD-H2h4 mice (15, 16) were obtained 
from Jackson Laboratory Inc. (Bar Harbor, 
ME, USA) and bred in the animal facility at 
Nagasaki University in a specific 
pathogen-free condition.  Both male and 
female mice were used for the current study.  
Animal care and all experimental procedures 
were performed in accordance with the 
Guideline for Animal Experimentation of 
Nagasaki University with approval of the 




   The cDNA for mouse TRAIL was kindly 
provided by Dr. S. Hirata at Kumamoto 
University, Japan (3).  The cDNA for mouse 
IDO was obtained by reverse 
transcription-polymerase chain reaction 
(RT-PCR) from total RNA extracted from 
splenocytes stimulated with 200 U/ml IFN- 
for 48 h, followed by sequence validation.   
Recombinant replication-defective, 
fiber-mutant adenoviruses expressing TRAIL, 
IDO or green fluorescent protein (GFP, as a 
control) (Ad-TRAIL, -IDO or –GFP, 
respectively) were constructed, amplified and 
purified as previously described (18).  
Infectivity of these fiber-mutant adenoviruses 
to a variety of cells is higher than that of wild 
type adenovirus (19).  
 
In vitro and in situ infection of adenovirus 
   For in vitro infection, COS cells were 
infected with Ad-TRAIL, -IDO or –GFP at a 
multiplicity of infection (MOI) of 10,000 
particles/cell for 24 h. 
   For in situ infection, NOD-H2h4 mice (6 
to 8 weeks old) were anesthetized with 
pentobarbital.  An approximately one 
cm-long midline incision was made on the 
anterior neck under sterile conditions.  The 
underlying submandibular salivary glands 
were separated to the both sides to visualize 
laryngotrachea and strap muscles.  The strap 
muscles were then cut to form a gutter in 
which 20 l PBS with/without adenovirus (5 
x 109 or 10 particles/mouse) was applied.  
This procedure allowed the direct contact of 
adenovirus with the thyroid glands.  After a 
few minutes of contact, the submandibular 
glands were returned to their normal position, 
and the skin incision was closed using 
conventional surgical procedures (20).   
 
Detection of TRAIL and GFP expression 
   In vitro expression of TRAIL and GFP in 
COS cells of mock-infected or infected with 
Ad-IDO or -TRAIL was analyzed on a 
 4
FACScan flow cytometry using CellQuest 
software (BD Biosciences PharMingen, San 
Diego, CA).  Phycoerythrin-conjugated 
anti-TRAIL monoclonal antibody (clone 
N2B2, eBioscience, San Diego, CA, USA) 
was used to stain the cells expressing TRAIL.   
   For detection of in situ expression of 
TRAIL, mice were infected with adenovirus 
(5 x 1010 particles/mouse), and 3 days later 
the thyroid cells were prepared by enzymatic 
digestion from the thyroid tissues as 
previously described (21) and seeded on 
10-cm dishes.  On the next days, the 
isolated thyroid cells were harvested and 
analyzed on a FACScan flow cytometry as 
described above.   
In situ expression of GFP was examined 
in the thyroids removed at 3 days, and 1, 4 
and 8 weeks after infection by a confocal 
laser scan microscope LSM5Pascal (Carl 
Zeiss, Tokyo, Japan).    
 
Detection of IDO expression 
   IDO expression was determined by 
western blotting with 20 g of total cell 
lysates prepared from COS cells of 
mock-infected or infected with Ad-IDO (for 
in vitro expression), or 40 g from 
mock-infected or Ad-IDO infected thyroid 
tissues (for in situ expression).  The signal 
was developed with polyclonal anti-IDO 
polyclonal antibody (22) and 
alkaliphosphatase ABC method (Vectastatin 
ABC kit, Vector Laboratories, Burlingame, 
CA).     
 
Induction of thyroiditis 
   Mice were supplied with 0.15 % sodium 
iodine (NaI) in the drinking water.  Groups 
of mice were infected with adenovirus twice 
(1 day before and 4 weeks after the beginning 
of NaI provision in the drinking water) or 
thrice (4 weeks and 1 day before, and 4 
weeks after, NaI supply) (see Fig. 2, A).  
Eight weeks after NaI provision, mice were 
euthanized, and the thyroid glands, blood and 
the spleen were harvested to determine the 
extent of thyroiditis, the titers of serum 
anti-Tg autoantibodies and cytokine 
expression levels, respectively.    
   In a therapeutic setting, adenovirus was 
infected to the thyroids on one occasion 4 
weeks after exposure of the mice for NaI.   
 
Evaluation of thyroiditis 
   Thyroid tissues were fixed in 10 % 
formalin and embedded in paraffin.  
Five-mm-thick sections were prepared and 
stained with hematoxylin and eosin (H & E).  
Thyroiditis was assessed for extent of 
lymphocyte infiltration as follows (23); grade 
0, normal thyroid; grade 1, less than 10 % 
lymphocytic infiltration of the thyroid; grade 
2, 10 to 30 % lymphocytic infiltration; grade 
3, 30 to 50 % lymphocytic infiltration; grade 
4, greater than 50 % lymphocytic infiltration.  
The final thyroiditis scores were expressed as 
means of at least 3 noncontiguous sections 
from each thyroid gland.   
 
ELISA assay for anti-Tg antibodies 
   Tg was purified from mouse thyroid 
glands as previously described (23).  ELISA 
wells were coated overnight with 100 l Tg 
protein (10 g/ml) and incubated with mouse 
sera (1:300 dilution).  After incubation with 
horseradish peroxidase conjugated 
anti-mouse IgG (BD Biosciences 
PharMingen), color was developed using 
orthophenylene diamine and H2O2 as substrate 
and optical density (OD) read at 492 nm.   
 
Reverse transcription and polymerase chain 
reaction (RT-PCR) 
   Total RNA (1 g) was extracted from the 
spleen using Isogen (WAKO, Tokyo, Japan) 
and reverse-transcribed to generate cDNA 
with SuperScript III (Invitrogen, Carlsbad, 
CA) and oligo-dT.  PCR was then 
performed with PrimeSTAR HS DNA 
polymerase (Takara, Tokyo, Japan) and the 
following primer pairs;  
IFN- forward primer: 
5’-CACGGCACAGTCAATGAAAG-3’;  
IFN- reverse primer: 
5’-CCTTGCTGTTGCTGAAGAAG-3’;  
IL-4 forward primer: 
5’-CCTGCTCTTCTTTCTCGAATGT-3’;  
IL-4 reverse primer: 5’- 
TTTCAGTGATGTGGACTTGGAC-3’;  
-actin forward primer: 
5’-CTGAACCCTAAGGCCAACCGTG-3’;  
-actin reverse primer: 
5’-AGCTCTTTGAGGTGCTCCAG-3’. 
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The intensity of specific bands for IFN- 
and IL-4 on an agarose gel electrophoresis 
was quantified by NIH image J software.  
Expression levels of -actin for each sample 
were used for data normalization.   
 
Immunohistochemistry 
The thyroid glands were embedded in 
Tissue-Tek OCT compound (Miles, Elkhart, 
IN), frozen in liquid nitrogen and cut by a 
cryostat into 6- to 7-μm-thick sections.   
CD4 and Foxp3 staining was performed 
as recently described (24).  Briefly, after 
fixing with cold acetone for 10 min at 4C and 
blocking non-specific reactions and 
endogenous biotin activity with Blocking 
One (Nacalai Tesque, Kyoto, Japan), the 
samples were incubated with the primary 
antibodies [rabbit anti–mouse Foxp3 (25) 
and/or hamster anti-mouse CD4 (H129.19; 
BD Biosciences Pharmingen)] for 1 h at 
room temperature and subsequently with the 
secondary antibodies (Alexa Fluor 555 goat 
anti-rabbit IgG and/or Alexa Fluor 488 goat 
anti-hamster IgG, both from BD Biosciences 
Pharmingen) for 1 h at room temperature, 
and then fixed for 10 min at 4 C in PBS 
containing 4% paraformaldehyde.   
For TUNEL staining, the sections were 
incubated with terminal deoxynucleotidyl 
transferase and fluorescein 
isothiocyanate-dUTP at 37 C for 60 min, 
according to the manufacturer’s instruction 
(Medical & Biological Laboratories Co., Ltd., 
Nagoya, Japan). 
All sections were analyzed with a 
confocal laser scan microscope LSM5Pascal 
(24).  Numbers of CD4+ T cells and 
CD4+Foxp3+ T cells, and of apoptotic cells 
were counted in 4 nonconsecutive 
microscopic fields in each tissue.   
 
Statistical analysis  
   Thyroiditis scores, and levels of 
antibodies and cytokine expression were 
analyzed by Student’s t-test.  A ‘p’ value of 






In vitro expression of IDO, TRAIL and GFP 
in COS cells infected with adenovirus 
   To confirm that adenovirus vectors we 
generated can express the transgenes, COS 
cells were infected with adenovirus at a MOI 
of 10,000 particles/cell.  One day later, the 
cells were harvested and subjected to western 
blotting or flow cytometric analysis.  
Approximately 40 kDa IDO protein was 
clearly detected in the cells infected with 
Ad-IDO, and not in Ad-GFP infected cells, 
by western blotting (Fig. 1, A).  Expression 
of TRAIL and GFP was also confirmed by 
flow cytometry in the cells infected with 
Ad-TRAIL and Ad-GFP, respectively (Fig. 1, 
B).   
 
In situ expression of GFP in the thyroid 
glands 
   To determine in vivo infectivity of 
adenovirus, the thyroid glands were directly 
infected with Ad-GFP (5 x 109 or 10 
particles/mouse) as described in the 
Materials and Methods and removed 3 days, 
and 1, 4 and 8 weeks later.  GFP expression 
was readily observed throughout the thyroid 
glands infected with higher amounts of 
Ad-GFP (5 x 1010 particles) 3 days 
(supplementary Fig. S1), and 1 and 4 weeks 
(not shown), but not 8 weeks, after infection.  
However, no fluorescence was detected in the 
thyroid glands infected with lower amounts 
of Ad-GFP (5 x 109 particles) at any time 
point.  Thus adenovirus-mediated transgene 
expression with 5 x 1010 particles/mouse is 
detectable and persists at least for 4 weeks.  
Therefore, the higher amounts of adenovirus 
were used in all the subsequent experiments.   
   In situ expression of IDO and TRAIL was 
also confirmed.  As for in vitro expression 
data, approximately 40 kDa IDO protein was 
detectable in western blotting with the lysates 
from the Ad-IDO infected thyroid tissues 
(Fig. 1, C).  Furthermore, TRAIL expression 
was also demonstrable in flow cytometry 
with thyroid cells enzymatically isolated 
from the Ad-TRAIL infected thyroid glands 
(Fig. 1, D).   
 
Suppression of thyroiditis, but not systemic 
anti-thyroid autoimmune responses, by in situ 
infection of Ad-TRAIL or Ad-IDO 
   In the first series of experiments, the 
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thyroids were infected in situ with Ad-TRAIL 
or Ad-IDO twice (1 day before and 4 weeks 
after beginning of NaI provision in the 
drinking water) (the solid arrows in Fig. 2, A).  
Infection of Ad-TRAIL or Ad-IDO 
significantly suppressed thyroiditis.  Thus 
the thyroiditis scores were decreased from 
3.73 + 0.46 (sham-operated mice, mean + 
S.D.) to 2.18 + 1.22 (p < 0.0001) by 
Ad-TRAIL and to 1.57 + 1.11 (p < 0.0001) 
by Ad-IDO (Fig. 2, B) (n = 15 for each 
group).  Infection of Ad-GFP did not 
influence thyroiditis scores.  The 
representative histology of thyroid glands 
was shown in the Fig. 3; normal thyroid 
gland in a naive mouse (A), grade 
2-thyroiditis in an Ad-TRAIL infected mouse 
(B) and grade 4-thyroiditis in an Ad-GFP 
infected mouse (C).     
   In the second set of experiments in which 
adenovirus infection was performed thrice 
starting 4 weeks before provision of NaI (the 
open arrows in Fig. 2, A), the suppressive 
effect appeared more profound than the first 
experiment; thyroiditis scores were declined 
from 3.43 + 0.59 to 1.74 + 1.02 (p < 0.0001) 
by Ad-TRAIL and to 1.35 + 0.98 (p < 
0.0001) by Ad-IDO (Fig. 2, C) (n = 10 for 
each group).     
   Whether regional expression of the 
immuno-regulatory molecules affect systemic 
immune response was investigated by 
measuring serum anti-Tg antibody titers and 
cytokine expression in spleen.  
Anti-Tg-antibody titers (Fig.4, A and B) were 
0.56 + 0.30, 0.61 + 0.36 and 0.52 + 0.28 
OD492 in sham-operated mice, and those 
infected with Ad-TRAIL or -IDO, 
respectively, in the first experiments shown 
in Fig. 2, B and 0.52 + 0.38, 0.49 + 0.34 and 
0.47 + 0.32 in these 3 groups in the second 
experiments in Fig. 2, C.   
   Expression levels of cytokine mRNAs in 
spleen were 7.21 + 1.18 versus 7.43 + 1.26 
arbitrary units for IFN- and 7.64 + 1.68 
versus 8.30 + 1.35 for IL-4 in mock-infected 
and Ad-TRAIL infected thyroids, 
respectively (Fig. 5).  Similarly comparable 
expression levels of IFN- and IL-4 mRNAs 
were observed between mock-infected and 
Ad-IDO infected thyroids (data not shown). 
  Thus, thyroidal TRAIL or IDO expression 
did not affect extrathyroidal immune 
responses (anti-Tg antibody titers and splenic 
cytokine expression) in both experiments. 
 
Accumulation of regulatory T cells (Treg) in 
the thyroid glands induced by expression of 
TRAIL 
   The mechanisms for TRAIL- and/or 
IDO-mediated immune suppression include 
an increase in number of naturally-occurring 
regulatory CD4+CD25+ T cells (Treg), a T 
cell subpopulation that negatively suppresses 
immune response (4, 26), and induction of 
apoptosis (5, 6, 14).  We therefore compared 
the ratios of Treg to CD4+ T cells and the 
percentage of apoptotic cells between the 
thyroids from control and TRAIL- or 
IDO-treated mice.  
T cells double positive for CD4 and 
Foxp3 were defined as Treg, because Foxp3 
is at present the most reliable molecular 
marker for Treg (27).  The ratio of Treg to 
CD4+ T cells remained unchanged in the 
periphery (data not shown).  In contrast, the 
ratio of Treg to CD4+ T cells measured by 
immunohistochemistry was significantly 
higher in Ad-TRAIL infected thyroids than in 
mock-infected thyroids: 16.4 + 3.8 versus 4.8 
+ 2.8 % (mean + S.D., n=3) (p < 0.01).  
These data indicate TRAIL-induction of Treg 
accumulation into the thyroid glands.  
Representative photographs for 
immunofluorescence are shown in Fig. 6.  
In contrast, IDO had no effect on Treg 
accumulation in the thyroids (data not 
shown).   
   Turning to induction of apoptosis, the 
number of apoptotic cells (lymphocytes and 
thyrocytes) was determined by TUNEL assay.  
No difference was observed between 
mock-infected and Ad-TRAIL or Ad-IDO 
infected thyroids (data not shown).   
 
Therapeutic usefulness of in situ infection of 
Ad-TRAIL 
   To evaluate the therapeutic potential of in 
situ infection by adenovirus expressing the 
immuno-regulatory molecules, mice were 
infected once with Ad-TRAIL 4 weeks after 
the beginning of NaI.  Anti-Tg antibodies 
were readily detected at this time point (data 
not shown), indicating that the anti-thyroid 
immune response is already established.  As 
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shown in Fig. 7, Ad-TRAIL moderately but 
significantly decreased the degree of 
thyroiditis (3.29 + 0.80 to 2.56 + 0.73, n = 15 
for each group; p < 0.05).  Thus in situ 
expression of TRAIL can also be 





   In the present study, we hypothesized that 
localized expression of the 
immuno-regulatory molecules such as 
TRAIL or IDO, as a therapeutic modality for 
organ-specific autoimmune diseases, would 
lead to immuno-suppression limited to the 
microenvironments surrounding the tissue of 
expression.  To verify our hypothesis, these 
immuno-regulatory molecules were 
expressed by recombinant adenovirus in the 
thyroid glands of NOD-H2h4 mice, a strain 
that provides a spontaneous animal model of 
autoimmune thyroiditis.    
   We first showed high efficiency of 
adenovirus infection to the thyroid glands, 
which persisted at least for a month.  This 
high infectivity and long-lasting transgene 
expression may be at least partly attributed to 
use of the fiber mutant adenovirus as 
mentioned in the Materials and Methods (19, 
28).  These findings enabled us to examine 
the effect of in situ expression of the 
immuno-regulatory molecules on thyroiditis 
in NOD-H2h4 mice.  We found that infection 
of Ad-TRAIL or Ad-IDO to the thyroid 
glands 1 day or 4 weeks prior to providing 
the mice with iodized water significantly 
suppressed thyroiditis.  These data clearly 
indicate that in situ expression of 
immuno-regulatory molecules efficiently 
protects the thyroid glands from autoimmune 
attack.  However, serum anti-Tg antibody 
titers and expression levels of cytokines IFN 
and IL-4 in the spleen were unaffected.  
Thus, the effect of intrathyroidal expression 
of immuno-regulatory molecules is confined 
to the thyroid glands, and does not impact 
systemic immunity.  It is essential for any 
treatment modality to avoid unnecessary 
systemic immune suppression.  Furthermore, 
we found that suppression of thyroiditis was 
observed when adenovirus was given after 
anti-thyroid immune response was induced, 
indicating that this approach is also 
therapeutically effective.  This finding is a 
highly critical issue in a clinical setting.  
Consequently, this type of immunological 
intervention may have a potential for treating 
organ-specific autoimmune diseases.   
   Similar studies have previously been 
conducted in an inducible mouse model of 
autoimmune thyroiditis by using IL-10 and 
Fas ligand as immuno-suppressive molecules 
and DNA plasmid as a gene delivery vehicle 
(29, 30).  Surprisingly, despite much lower 
efficacy of gene transfer by non-viral plasmid 
vector than by adenovirus, local expression 
of IL-10 or Fas ligand by plasmid suppressed 
not only intrathyroidal lymphocyte 
infiltration but also systemic anti-thyroid 
immune response.  These data are 
contradictory to our current findings.  It is 
unclear how these distinct results can be 
reconciled at present.   
Adenovirus-mediated localized IDO 
expression has recently been shown to be 
effective at (i) protecting the transplanted 
islets from NOD diabetogenic T cells (12) 
and (ii) suppressing allograft rejection in lung 
transplantation (13).  In addition, 
intra-articular adenoviral-mediated TRAIL 
expression has also been shown to be 
beneficial for suppressing arthritis (6, 31).  
As for our present report, these studies were 
also conducted as attempts to control 
abnormal autoimmune responses locally.   
   The mechanisms of actions of TRAIL and 
IDO on immune system are wide-ranging.  
One of the common mechanisms is 
engagement of Treg (4, 26).  For examples, 
Hirata et al. (4) reported that TRAIL+ DCs 
activate and augment proliferation of 
CD4+CD25+ T cells, and Fallarino et al. (26) 
showed that naive T cells differentiate to Treg 
by co-culture with IDO+ DCs.  Our results 
are consistent with those of Hirata et al. (4) 
in that TRAIL increased the ratios of Treg to 
CD4+ T cells in the lesion.  Wang et al. (32) 
studied the effect of systemic administration 
of TRAIL protein on thyroiditis in a transfer 
model of thyroiditis in mice.  As expected, 
injection of TRAIL suppressed not only 
thyroiditis, but also splenocyte proliferation 
and IFN- production, as well as serum 
anti-Tg antibody titers.  In their more recent 
study, TRAIL is also reported to enhance 
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CD4+CD25+CD45RBlow Treg (33).  
However, in our study, accumulation of Treg 
was not observed when IDO was expressed 
in non-professional antigen presenting 
thyroid cells.   
   Some, but not all (5, 6, 14), 
publications reported that TRAIL and IDO 
also induce apoptosis and/or inhibit 
proliferation in lymphocytes.  In arthritis 
models, for examples, one group (31) 
demonstrated apoptosis induction by TRAIL 
in abnormally proliferating synovial cells in a 
rabbit model, while another group (6) showed 
prevention of proliferation of both synovial 
cells and arthritogenic lymphocytes by 
TRAIL in a mouse model.  In the present 
study, no significant increase in apoptotic 
lymphocytes/thyrocytes by TRAIL or IDO 
was observed.  Therefore, all the data 
suggest that accumulation of Treg may be a 
mechanism for suppression of thyroiditis by 
TRAIL, and that IDO may exert its inhibitory 
action by suppressing proliferation of 
lymphocytes rather than inducing apoptosis 
or accumulating Treg in our study.   
   One potential disadvantage of our study 
is transient expression of the transgene 
induced using adenovirus.  It should be 
however emphasized that our investigation 
was performed as a proof-of-principle 
experiment and did not examine very 
long-term effect of adenovirus-mediated 
expression of immuno-regulatory molecules 
on thyroiditis.  Permanent transgene 
expression by other viral vectors such as 
retrovirus or adeno-associated virus may be 
more feasible in the future.  Another 
drawback is the relatively small therapeutic 
effect we observed as shown in Fig. 7.  
However, disease progress may be much 
faster in NOD-H2h4 mice as compared to the 
natural disease development of human 
Hashimoto’s thyroiditis.  Consequently, the 
efficacy of our approach may be more 
pronounced when tested in a clinical setting.  
   Finally, we conclude that this type of 
immunological intervention, although it does 
not suppress the autoimmune reaction itself, 
has the potential for treating organ-specific 
autoimmune diseases.  Further studies will 
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Figure 1.  In vitro and in situ expression of TRAIL, IDO and GFP proteins.  In A and C, the 
cell lysates from COS cells infected with Ad-IDO or Ad-GFP (negative control) (A) or the 
thyroid glands of mock-infected or infected with Ad-IDO (C) were subjected to western blotting 
as described in the Materials and Methods.  In B and D, COS cells of mock-infected or 
infected with Ad-TRAIL or Ad-GFP (B) or thyroid cells isolated from the thyroids of 
mock-infected or infected with Ad-TRAIL (D) were analyzed by flow cytometry as described in 
the Materials and Methods.  
 
Figure 2.  Suppression of thyroiditis in NOD-H2h4 mice infected with Ad-TRAIL or Ad-IDO.  
A, Schedule for investigating the effect of adenovirus infection on thyroiditis.  Solid and open 
arrows depict the timing of adenovirus infection in B and C, respectively.  Mice were 
mock-infected or infected with Ad-GFP, Ad-TRAIL or Ad-IDO twice (B) or thrice (C) and were 
maintained in the presence or absence of NaI in the drinking water for 8 weeks.  B and C, The 
thyroid glands were examined with H & E staining, and the thyroiditis scores were assessed as 
described in the Materials and Methods.  *, p < 0.01.  
 
Figure 3.  Representative histology of the thyroid glands in NOD-H2h4 mice. A, grade 0 in a 
naïve mouse, B, grade 2-thyroiditis in Ad-TRAIL treated mouse, C, grade 4-thyroidiits in 
Ad-GFP treated mouse.  
 
Figure 4.  Lack of effect of Ad-TRAIL or Ad-IDO infection on anti-Tg antibody titers.  
Anti-Tg antibody titers in sera from the mice shown in the Fig. 2, B and C were determined by 
ELISA (see the Materials and Methods) and are shown in A and B, respectively.  
 
Figure 5.  Lack of effect of Ad-TRAIL or Ad-IDO infection on expression levels of mRNAs 
for IFN- (A) and IL-4 (B) in the thyroid glands.  Total RNA extracted from the thyroid glands 
from mice of mock-infected or infected with Ad-TRAIL were subjected to RT-PCR as described 
in the Materials and Methods.  A and B, representative pictures for IFN-, IL-4 and -actin 
mRNA expression in control and Ad-TRAIL infected thyroids.  C and D, quantification of 
expression levels of IFN- and IL-4 mRNAs normalized by -actin mRNA expression.  Means 
+ S.D. (n =3).  
 
Figure 6.  Expression of CD4 and Foxp3 in the thyroid glands.  The mock-infected (A) or 
Ad-TRAIL-infected (B) thyroid glands were stained with anti-CD4 and anti-FoxP3 antibodies 
as described in the Materials and Methods.  Green and red indicate CD4 and Foxp3, 
respectively, expression.  Magnification, x400.  
 
Figure 7.  Therapeutic usefullness of Ad-TRAIL.  Mice were mock-infected or infected with 
Ad-TRAIL 4 weeks after exposure to NaI in the drinking water and maintained on iodized water 
for an additional 4 weeks.  The thyroid glands were then examined with H & E staining, and 
the thyroiditis scores were assessed as described (the Materials and Methods).  The individual 
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